Actively Recruiting
Dosimetry and Preliminary Clinical Application Study of a Novel Probe Targeting CD73
Led by First Affiliated Hospital of Fujian Medical University · Updated on 2025-05-30
30
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
As a new CD73-targeted PET radiotracer, 68Ga-dPNE, is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 68Ga-dPNE in human volunteers. Furthermover, we conducted a comparative analysis of 68Ga-dPNE and 18F-FDG imaging to assess both the radiation dosimetry and diagnostic efficacy of 68Ga-dPNE.
CONDITIONS
Official Title
Dosimetry and Preliminary Clinical Application Study of a Novel Probe Targeting CD73
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent and be able to follow up.
You will not qualify if you...
- Pregnant or lactational women
- Severe hepatic insufficiency
- Severe renal insufficiency
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China, 350005
Actively Recruiting
Research Team
W
Weibing Miao, MD
CONTACT
R
Rong Lin, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here